Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:Zevaquenabant CAS:1998760-00-1 Package:25mg/RMB 10600
|
|
| 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- Basic information |
| 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- Chemical Properties |
Boiling point | 621.2±65.0 °C(Predicted) | density | 1.42±0.1 g/cm3(Predicted) | pka | 6.70±0.60(Predicted) |
| 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- Usage And Synthesis |
Uses | Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1]. | in vivo | Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. Animal Model: | 6-week-old male C57Bl/6J mice (diet-induced obesity)[1] | Dosage: | 3 mg/kg | Administration: | P.o.; for 28 days | Result: | Improved kidney morphology and function in diet-induced obese mice.
|
| IC 50 | CB1 | References | [1] Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127. DOI:10.1111/bph.14849 |
| 1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- Preparation Products And Raw materials |
|